Using tumor gene data to help guide care for lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study looks at gene-related information from a lung tumor sample and pairs it with special imaging to better understand non-small cell lung cancer. If you have a confirmed diagnosis and the right samples/tests, this may help researchers match patients to the most useful information for planning treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 20 years old
- You have a confirmed diagnosis of non-small cell lung cancer
- You have had complete cancer staging tests already
- You have a stored tissue sample from your main lung tumor before starting treatment
- You can do an FDG PET/CT scan and the images are expected to be clear enough to read
- Your cancer comes from the lung primary tumor (not another primary cancer)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at lung cancer tumor samples and blood to find DNA changes (gene changes) that may be driving the cancer. The results could help researchers better understand lung cancer and guide future treatments.
This study is testing a new way to help find lung cancer earlier by combining imaging (like CT scans) with a blood test that looks at DNA changes. If you have lung cancer and haven't started treatment yet, participating may help improve future detection methods.
This study looks at whether a special PET scan can help predict if lung cancer has a certain gene change (EGFR) that might affect treatment options. It aims to see if the scan can be used instead of a biopsy to find this gene change.
This study uses an AI system that looks at your PET/CT scan images to figure out the exact type and genetic makeup of your non-small cell lung cancer. The goal is to improve how doctors classify and treat your cancer without needing extra invasive tests.
This study collects and analyzes tumor tissue from people with early-stage non-small cell lung cancer who are planning surgery. It may help researchers learn more about the cancer by studying samples taken at the time of your operation.
This study looks at genetic (DNA) information to find a marker that can help predict whether immunotherapy will work for lung cancer. If you’ve already received an immune checkpoint inhibitor, your tumor/genetic data may be analyzed to look for clues that guide treatment.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.